Overview
Compugen Q3 revenue of $1.9 mln beats analyst expectations but declines from prior year
Net loss for Q3 was $6.98 mln, compared to a net profit last year
Outlook
Company expects cash reserves to fund operations into Q3 2027
Company advancing GS-0321 trial, licensed to Gilead
Result Drivers
FINANCIAL POSITION - Solid financial position with cash runway expected to fund operations into Q3 2027
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $1.89 mln | $1.47 mln (3 Analysts) |
Q3 EPS | -$0.07 | ||
Q3 Net Income | -$6.98 mln | ||
Q3 Gross Profit | $241,000 | ||
Q3 Operating Expenses | $8.13 mln | ||
Q3 Operating Income | -$7.89 mln |
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Compugen Ltd is $4.00, about 59.5% above its November 7 closing price of $1.62
Press Release: ID:nPn8w1YCla
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)